192869-09-3

Basic information

• Product Name: 2-iodo-3,4-dimethoxybenzonitrile
• Synonyms: 2-Iodo-3,4-dimethoxybenzonitrile; benzonitrile, 2-iodo-3,4-dimethoxy-
• CAS NO: 192869-09-3
• Molecular Formula: C₉H₈INO₂
• Molecular Weight: 289.0698
• Mol File: 192869-09-3.mol

Chemical Properties

• Boiling Point: 358.307°C at 760 mmHg
• Flash Point: 170.498°C
• Density: 1.757g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.609
• CAS DataBase Reference: 2-iodo-3,4-dimethoxybenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-iodo-3,4-dimethoxybenzonitrile(192869-09-3)
• EPA Substance Registry System: 2-iodo-3,4-dimethoxybenzonitrile(192869-09-3)

Safety Data

• Hazardous Substances Data: 192869-09-3(Hazardous Substances Data)

Relevant articles and documents

Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia

Compounds of formula I, STR1whereinR 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms;R 2 represents H or C 1-6 alkoxy optionally substituted by one or more fluorine atoms;R 3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted;R 4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted;X represents CH or N; andL is absent,or represents a cyclic group of formula Ia, STR2or represents a chain of formula Ib, STR3and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.

Quinoline and quinazoline compounds useful in therapy

PCT No. PCT/EP96/05609 Sec. 371 Date Jun. 17, 1998 Sec. 102(e) Date Jun. 17, 1998 PCT Filed Dec. 5, 1996 PCT Pub. No. WO97/23462 PCT Pub. Date Jul. 3, 1997The invention provides compounds of formula (I), wherein R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms; R2 represents H or C1-6 alkoxy optionally substituted by one or more fluorine atoms; R3 represents one or more groups independently selected from H, halogen, C1-4 alkoxy and CF3; in addition, R2 and one R3 group may together represent -OCH2-, the methylene group being attached to the ortho-position of the pendant phenyl ring; R4 represents a 4-, 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring containing 1 or 2 heteroatoms selected from N, O and S, the ring system as a whole being optionally substituted; X represents CH or N; and L is absent or represents a cyclic group or an open chain group; and pharmaceutically acceptable salts thereof. The compounds of formula (I) are useful in the treatment of inter alia benign prostatic hyperplasia.